Data S1: patients and methods
Patients may have received prior lapatinib or letrozole treatment but had to have washed out for at least five half-lives prior to study entry (5 and 10 days for lapatinib and letrozole, respectively). Patients who had previously experienced moderate to severe AEs related to lapatinib or letrozole were not enrolled. Other exclusion criteria were use of neoadjuvant or adjuvant therapy including chemotherapy, antiestrogens, and trastuzumab <1 year and aromatase inhibitors <3 months before study entry; patients requiring a pharmacological dose of glucocorticoids (apart from replacement doses or topical, intra-ocular, or inhaled application); prior treatment with agents specifically targeting insulin-like growth factor receptors; type 1 or uncontrolled type 2 diabetes; unwillingness or inability to receive metformin; cataract(s), retinopathy, or other ocular disease; thyroid disease; uncontrolled intercurrent illnesses; unstable cardiovascular disease; known or suspected human immunodeficiency virus, or hepatitis B or C infection; inflammatory diseases of the gastrointestinal tract; malabsorption syndrome; recent major surgery; any clinically significant deviations in physical examination, vital signs, ECG, or clinical laboratory determination; history of other malignancy unless disease-free ≥5 years and not including resected non-melanoma skin cancer or successfully treated in situ carcinoma; QTcF >450 msec or any clinically significant ECG abnormalities; and use of strong inhibitors/inducers of CYP3A4/5 or herbal medications within 1 week, drugs for prevention of graft-versus-host disease or transplant rejection within 2 months, or hematopoietic growth factors and erythropoiesis-stimulating agents within 3 weeks before the administration of study medication.
Treatment
All drugs were administered concomitantly orally once daily on an outpatient basis. KW-2450 (Kyowa Kirin Pharmaceutical Development, Inc.) was administered on a continuous daily schedule after overnight fasting that was maintained until 1 hour after the dose was given. A 2-hour fast after the dose was given was required on all days that samples were obtained for pharmacokinetic and pharmacodynamic analyses. Lapatinib (Tykerb ® , GlaxoSmithKline) and letrozole (Femara ® , Novartis Pharmaceuticals Co.) were obtained from commercial sources. Lapatinib was administered at least 1 hour before or 1 hour after a meal. Letrozole was taken without regard to meals. Patients could continue treatment for up to 12 months, until disease progression, drug intolerance, unacceptable toxicity, consent withdrawal, or non-compliance. Dose modifications of KW-2450 and lapatinib were pre-specified in the case of defined toxicities but not for letrozole.
Assessments
Demographic data and medical history were determined during screening. Physical examination, ECOG performance status, vital signs/weight, hematology, and AEs were determined during screening, on Days 1 (study entry), 29, and 43, and then every 2 weeks including end of treatment, and additionally on Days 8 and 15 for vitals/signs, hematology/chemistry, and AEs. HbA1c was determined during screening, on Day 29, and then every 2 weeks. Urinalysis was performed during screening and at the end of treatment. 12-lead ECG was performed during screening, on Days 1 and 29, and at the end of treatment. Cardiac ejection fraction on ECG or MUGA scan was determined during screening and every 12 weeks.
CT and MRI scanning of disease sites was performed during screening and every 8 weeks with response evaluated a modified version of RECIST 1.1 guidelines. PFS was defined from the time of first day of treatment until disease progression or death.
AEs were classified and graded according to CTCAE v.4.03. Treatment-related AEs were those classified as possibly, probably, or definitely related to the individual study drugs by the investigator. Patients were considered evaluable for toxicity once therapy had started and were evaluable for efficacy if they had baseline and at least one on-study assessment of tumor response. DLTs were defined by any of the following events occurring within 30 days of the start of treatment that was considered definitely, probably, or possibly related to study medication: fasting hyperglycemia Grade 3; hyperglycemia Grade 4; cardiac toxicity Grade ≥2; any other AE Grade ≥3 except for symptomatic AEs, such as nausea, vomiting, and diarrhea, if they were reduced to Grade <3 within 72 hours with standard supportive measures; neutropenia Grade ≥4 for >7 days; and thrombocytopenia Grade ≥4.
Pharmacokinetics
Blood samples for pharmacokinetic analysis were drawn at 0 (pre-dose), 1, 2, 4, 8, and 24 hours after dosing on Days 1 and 29. Fasting conditions were maintained at 0, 1, 2, and 24 hours. Plasma samples were analyzed for KW-2450, lapatinib, and letrozole by using validated high performance liquid chromatographic methods with tandem mass spectrometry detection and automated extraction methods. The standard curve ranges were 4.96-4955, 5.0-500, and 40.0-4000 ng/mL for KW-2450, letrozole, and lapatinib, respectively. Pharmacokinetic parameters were determined by non-compartmental methods using WinNonlin ® v.6.3 (Pharsight Co., Princeton, NJ).
Pharmacodynamics
Blood samples were taken at 0, 2, and 24 hours after dosing on Days 1 and 29 for determination of plasma glucose and insulin. Plasma samples were analyzed for insulin-like growth factor-1, insulin-like growth factor binding protein-3, and growth hormone. .65 a n = 7 b n = 4 c n = 2 d n = 1 AUC0-t, area under the plasma concentration-time curve from time zero to last measurable time point; Cmax, maximum plasma concentration; R, accumulation ratio calculated as ratio of day 29 AUC0-t/day 1 AUC0-t; SD, standard deviation; tmax, time to Cmax; t1/2, terminal elimination half-life; Vz/F, apparent volume of distribution based on terminal elimination phase.
